Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease
Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease
Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be avoided.
Following screening for eligibility, women will be studied at baseline and then randomized to one of two groups:
Group A administered Femoston Conti - oral oestradiol 17β 0.5 mg/dydrogesterone 2.5 mg daily for the duration of the treatment phase (24 weeks)
Group B administered ½ Evorel Conti patches - trans-dermal Estradiol 25 mcg/norethisterone acetate 85 mcg (½ Evorel Conti patches) daily for the duration of the treatment phase (24 weeks).
Studies will be repeated after 6 months of therapy at the follow up visit.
Inclusion Criteria:
Exclusion Criteria:
j.stevenson@imperial.ac.uk0207 351 8112
m.gerval@imperial.ac.uk07734386042
London, SW10 9NH, United Kingdom
n.panay@imperial.ac.uk0203 331 8112
n.panay@imperial.ac.uk0203 331 8112